FIH Inhibitor Compounds for NASH Lipid Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonalcoholic steatohepatitis (NASH) are inadequate, with no FDA-approved drugs available, and existing therapies only delay disease progression, highlighting the need for new therapeutic approaches that target lipid metabolic diseases effectively.
Innovation Solution
Development of 3-hydroxy-5-(isoxazol-5-yl)picolinoyl glycine compounds that act as first-in-class inhibitors of factor inhibiting hypoxia-inducible factor (FIH), which accelerate lipid metabolism, thereby treating hyperlipidemia, obesity, and NASH by inhibiting FIH with optimal nanomolar concentration IC50 values.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conservative treatment schemes are used for NASH, then disease progression is delayed, but therapeutic efficacy is insufficient and no FDA-approved drugs are available
Solution Approach 1:
The patent applies parameter changes by developing small molecule inhibitors with optimized chemical structures (formula I) that target FIH enzyme activity. The compounds feature specific molecular parameters including aromatic rings, heterocyclic groups, and functional moieties that enable nanomolar inhibition of FIH, representing a fundamental change in therapeutic parameters for NASH treatment
Solution Approach 2:
The patent uses FIH (factor inhibiting HIF) as an intermediary target to treat NASH. By inhibiting FIH, the compounds indirectly activate HIF-1α signaling pathway, which then regulates downstream genes involved in lipid metabolism, inflammation, and fibrosis. This intermediary mechanism provides a novel therapeutic approach that bridges molecular target inhibition to clinical disease modification
2Productivity
If FIH deficiency is induced to improve lipid metabolism, then oxidative metabolism increases and body weight decreases, but the mechanism is complex and requires precise inhibition
Solution Approach 1:
The patent extracts and isolates the FIH enzyme as the specific therapeutic target, separating its inhibitory effect from the complex downstream metabolic pathways. By designing compounds that specifically bind to and inhibit FIH active site, the patent simplifies the therapeutic mechanism to a single primary action (FIH inhibition) while allowing the complex metabolic effects to occur naturally downstream
Solution Approach 2:
The patent segments the metabolic regulation process by targeting a specific control point (FIH enzyme) rather than attempting to modulate entire metabolic pathways. This segmentation allows precise control at the FIH-HIF axis while letting downstream metabolic processes (oxidative metabolism, lipid breakdown, energy expenditure) self-regulate, reducing the complexity of direct intervention in multiple pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds significantly reduce triglyceride levels, restore normal fat metabolism, and demonstrate efficacy in both cellular and animal models, providing a new mechanism for treating lipid metabolic diseases, including NASH, with potential for broad clinical application.
Implementation Method 1
FIH small molecule inhibitors can improve lipid metabolic diseases such ashyperlipidemia, obesity, NASH, etc. by accelerating the mechanism of lipidmetabolism. No FIH small molecule inhibitors have been reported before
Implementation Method 2
In the presence of ferrous ions, oxygen, and 2OG, the specific asparagine residue of the HIF-α C-terminal transactivation domain (CTAD) can be hydroxylated, so that the binding capacity of HIF-α to a transcriptional enhancer p300/CBP is greatly reduced
Data Source
AI summary
A series of 3-hydroxy-5-(isoxazol-5-yl) pyridine formylglycine compounds, a preparation method, a pharmaceutical composition, and the use. A structure of the compounds is shown as formula (I), and the compound derivatives comprise pharmaceutically acceptable salt thereof. The compounds and the pharmaceutical composition thereof have a high inhibition effect on HIF inhibition factors, and the activity can optimally reach the nano-molar concentration level, so that the compounds can be used for preparing a drug for treating fat metabolic diseases.